Literature summary for 3.4.14.5 extracted from

Nauck, M.A.; Meininger, G.; Sheng, D.; Terranella, L.; Stein, P.P.; Stein, P.P.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial (2007), Diabetes Obes. Metab., 9, 194-205.

Search for more literature for 3.4.14.5

Application

Application	Comment	Organism
medicine	the addition of sitagliptin compared with glipizide provides similar HbA1c-lowering efficacy over 52 weeks in patients with type 2 diabetes on ongoing metformin therapy. Sitagliptin is generally well tolerated, with a lower risk of hypoglycaemia relative to glipizide and with weight loss compared with weight gain with glipizide	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
sitagliptin	the addition of sitagliptin compared with glipizide provides similar HbA1c-lowering efficacy over 52 weeks in patients with type 2 diabetes on ongoing metformin therapy. Sitagliptin is generally well tolerated, with a lower risk of hypoglycaemia relative to glipizide and with weight loss compared with weight gain with glipizide	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	patients with type 2 diabetes	-

Synonyms

Synonyms	Comment	Organism
dipeptidyl peptidase-4	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)